Premium
Ciclosporin in psoriasis clinical practice: an international consensus statement
Author(s) -
Griffiths C.E.M.,
Dubertret L.,
Ellis C.N.,
Finlay A.Y.,
Finzi A.F.,
Ho V.C.,
Johnston A.,
Katsambas A.,
Lison AE.,
Naeyaert J.M.,
Nakagawa H.,
Paul C.,
Vanaclocha F.
Publication year - 2004
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.0366-077x.2004.05949.x
Subject(s) - ciclosporin , psoriasis , medicine , statement (logic) , dermatology , consensus conference , medline , intensive care medicine , chemotherapy , political science , law
Summary The main recommendations for the use of ciclosporin in the management of psoriasis are: (i) intermittent short courses (average of 12 weeks duration) of ciclosporin are preferable; (ii) ciclosporin should be given in the dose range 2·5–5·0 mg kg −1 day −1 (doses greater than 5·0 mg kg −1 day −1 should only be given in exceptional circumstances); (iii) treatment regimens should be tailored to the needs of each patient; (iv) selection of patients should take into account psychosocial disability, as well as clinical extent of disease and failure of previous treatment; (v) each patient's renal function (as measured by serum creatinine) should be thoroughly assessed before and during treatment; (vi) each patient's blood pressure should be carefully monitored before and during treatment; (vii) adherence to treatment guidelines substantially reduces the risk of adverse events; (viii) long‐term continuous ciclosporin therapy may be appropriate in a subgroup of patients; however, duration of treatment should be kept below 2 years whenever possible; and (ix) when long‐term continuous ciclosporin therapy is necessary, annual evaluation of glomerular filtration rate may be useful to accurately monitor renal function.